


# Asedat Software for Hospital-based cancer registries

ENCR Workshop on Software, Applications and IT Tools for Data Collection and Quality Assurance in Cancer Registries Jordi Gálvez

18/10/2024



# International standards for population-based cancer registries













### **Hospital-based cancer registries**

#### **Characteristics Objectives**

Patients diagnosed/treat ed in a hospital

#### Case identification exhaustivity

Information collection regulations

Validate cases from primary information sources (prevalent, multiple)

Hospital administrative goals:

- Clinical evaluation
- Clinical follow up
- ✓ Deffinition of hospital needs

Clinical and epidemiological projects

#### Use

NOT SUITABLE for population health planning

**Biased sample** (reference center, experience on certain cancer types, sanitary circuits, access of the population to enter a center, ...)

#### European Network of Cancer Registries





#### Subset

of the total number of population cancer patients

### **ICO-ICS Hospital-based cancer registry**

#### **MULTICENTRIC (6 centers):**

**Badalona:** H. Germans Trias i Pujol / ICO Badalona; **Girona:** H. Dr. Josep Trueta / ICO Girona; **L'Hospitalet de Llobregat:** H. Bellvitge/ ICO L'Hospitalet

#### **INCLUSION CRITERIA:**

- 1. PRIMARY tumors that contact for the first time in an RTH ICO-ICS center.
- 2. The contact of the primary tumor in the RTH ICO-ICS centers has been to make the diagnosis or administer oncological treatments.

#### Morphology:

- 3. Any invasive cancer regardless of topography
- 4. Any tumor of the central nervous system regardless of tumor behavior (benign, uncertain, malignant)







# Hospital registry data sources (1)

Source	Data availability	Structured?	Variables
Hospital discharge	Diagnoses and procedures	ICD-10	Oncological surgery, elective/emergency surgery, hospital mortality, average hospital stay, comorbidity
Pathology records	Morphology, histology, bihaviour, pTN, ypTN, hormone receptors, biomarkers	Snomed-CT terminology	Morphology, diagnostic method, first pathological diagnosis date
Outpatients records	Diagnoses	ICD-10	Tumour site, number of hospital visits
Clinical trials	Diagnoses	Unstructured (mapping to ICD-O-3.2)	Tumour and treatment related variables







# Hospital registry data sources (2)

Source	Data availability	Structured?	Variables
Chemotherapy records	Diagnoses, chemotherapy, immunotherapy	Unstructured (mapping to ICD-O- 3.2)	Tumour and chemotherapy related, biomarkers
Radiotherapy records	Diagnoses, radiotherapy scheme	ICD-9 (mapping to ICD-O- 3.2)	Tumour and radiotherapy related
Haematological laboratory	Cytogenetics and molecular biology records	Unstructured (mapping to ICD-O- 3.2)	Specification of haematological tumours
Tumour committees	Diagnoses	Unstructured (mapping to ICD-O- 3.2)	Tumour site, stage







### Hospital registry data sources (3)


Source	Data availability	Structured?	Variables
Hospital admissions	Personal information	Local codification	Sex, birth date, residence
Mortality records	Vital status	ICD-10	Date and cause of death
Hospital registry	Historical data	ICD-O-3,	Prevalent tumours, multiple tumours







### **Catalan Pathology Registry structure**









#### From SNOMED CT to ICD-0-3.2

#### Journal of Biomedical Informatics 78 (2018) 167-176 Contents lists available at ScienceDirect



Journal of Biomedical Informatics

journal homepage: www.elsevier.com/locate/yjbin

Definition of a SNOMED CT pathology subset and microglossary, based on 1.17 million biological samples from the Catalan Pathology Registry



Xavier Sanz<sup>a</sup>, Laura Pareja<sup>a</sup>, Ariadna Rius<sup>b</sup>, Pepi Rodenas<sup>c</sup>, Núria Abdón<sup>b</sup>, Jordi Gálvez<sup>a</sup>, Laura Esteban<sup>a</sup>, Josep Maria Escribà<sup>a,d</sup>, Josep Maria Borràs<sup>a,d</sup>, Josepa Ribes<sup>a,d,\*</sup>

<sup>a</sup> Catalan Cancer Plan, Department of Health of Catalonia, Avd. Gran Via de l'Hospitalet, 199-203, 08908 Hospitalet del Llobregat, Barcelona, Spain <sup>b</sup> Office of Standards and Interoperability of TicSalut Foundation, Department of Health, Av. Ernest Lluch, 32, 6a Planta, 08302 Mataró, Barcelona, Spain <sup>c</sup> Catalan Electronic Health Record, Department of Health of Catalonia, Travessera de les Corts, 131-159, Edifici Ave Maria, 08028 Barcelona, Spain <sup>d</sup> Department of Clinical Sciences, University of Barcelona (UB), Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain



International Journal of Medical Informatics 141 (2020) 104167



How cancer registries can detect neoplasms in pathology laboratories that code with SNOMED CT terminology? An actual, simple and flexible solution

Check for updates

Xavier Sanz<sup>a</sup>, Laura Pareja<sup>a</sup>, Ariadna Rius<sup>b</sup>, Jordi Gálvez<sup>a</sup>, Josep Maria Escribà<sup>a</sup>, Laura Esteban<sup>a</sup>, Josep M. Borràs<sup>a</sup>, Josepa Ribes<sup>a,c,\*</sup>

<sup>a</sup> Catalan Cancer Plan, Department of Health of Catalonia, Avd. Gran Via de l'Hospitalet, 199-203, 08908, Hospitalet del Llobregat, Barcelona, Spain <sup>b</sup> Office of Standards and Interoperability of TicSalut Social Foundation, Department of Health, Av. Ernest Lluch, 32, 6a Planta, 08302, Mataró, Barcelona, Spain <sup>c</sup> Department of Clinical Sciences, University of Barcelona (UB), Carrer de la Feixa Llarga, s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain









#### **Final subsets**

Neoplastic subset



Topographic subset









### **Software for hospital-based tumour registries** (ASEDAT)








Gac Sanit. 2005;19(3):221-8



European Commission

#### **Input source data**

- First step: select patients with a malign code within available data sources on the time lapse to be processed
- Second step: for selected patients, every data available (malign and benign, from every time lapse) through data sources are included in the input data tables to be processed with Asedat algorithm
- Patient matching: all data sources are linked through the unique patient hospital identifyer









- Based on technical report "Automated Data Collection on Cancer Registration" by IARC
- Equivalency groups for topography and morphology
- Groups must be coherent through data sources
  - Otherwise, manual revision is needed
- Multiple tumours can be automatically collected if enough data is available (coherent topography through data sources and morpholgy in Pathology Records) and tumours sites and morphologies are from different, non-related equivalency groups







# Automatically collected tumour data

- Topography site
- Morphology
- First hospital incidence date
- Basis of diagnosis
- TNM and stage from pathology records
- Associated treatments

More data can be manually added







### **Treatments data collection (1)**

#### Surgical and trasplants treatments collection

Hospital discharges have the surgical procedures coded using ICD-9 and ICD-10. Asedat tries to collect tumor treatments by examining these codes. Rules for associating a treatment to a tumor are defined as follow:

- The main diagnose of the discharge must be a neoplasm
- A dictionary is defined for treatment codes associated to a certain tumor location. At least one of the procedure codes of the discharge must appear in this dictionary associated to the neoplasm of the main diagnose
- Additional data can be collected from identified discharges: admitance date, discharge date, average stance, re-admitances, ....

The dictionary comprises more than 80.000 combinations of ICD tumor diagnoses (at 4 digits level) and ICD surgical procedure codes. Both ICD-9 and ICD-10 codes are included. This dictionary also includes trasplant codes







## **Treatments data collection (2)**

#### **Chemotherapy treatments collection**

Chemotherapy treatments are collected from the ESPOQ software database. The main issue is that tumor site and morphology are not coded in this database, but a literal is constructed when ESPOQ users select the protocol to a treatment. These literals include tumor site and sometimes morphology, so a dictionary is constructed to codify them from the literal. Currently, up to 3400 literals have been converted to ICD-O-3 codes.

Because this issue only happens at ESPOQ databases, and Asedat is designed to be general purpose for any registry using any kind of chemotherapy database, the dictionary is not included in the Asedat package, so the conversion is made before Asedat is executed. Asedat expects the input chemotherapy database to have tumor site and morphology coded in ICD-O-3. Date of prescription and date of administration are also collected.

Work in progress: ATC codes, types of chemotherapy (immunotherapy, cytostatics ...)







### **Treatments data collection (3)**

#### **Radiotherapy treatments collection**

- Radiotherapy treatments are collected from the ICO database. Here tumor site is available, coded in ICD-9 at three digits level and full ICD-10 codes since 2019, but no morphology code or descriptor is present, so unknown morphology is assumed (M-80003 code) until it can be collected from other sources. A simple conversion to ICD-O-3 site codes is performed, and treatment is collected including several variables (starting and ending dates, dose, number of sessions...)
- Brachytherapy and in-surgery radiotherapy can also be identified on hospital discharge records through ICD-10 codes







#### **Manual data revision**

#### Cercador codis ICD-O-3 online | International Classification of Diseases for Oncology

Data Incidència Hospitalària	
03/05/2010	
Topografia 🔍 c509	
C509 - MAMA, SAI	~
Lateralitat 🥑	
	~
Grau Urològic 🍘	
	~

23/01/2019	
Morfologia Q m-85003	
M-85003 - Carcinoma de mama	$\sim$
Comité de tumors	
Sí	~
Grau SNC 🕢	

23/01/2019	
Mètode Dx	
7 - Biòpsia de tumor principal	~
Grau diferenciació 💡	
6: Cèl·lula B, Pre-B; precursor B	~
Grau Neuroendocrins	
	~

Tumors sólids

#### Estadiatge al diagnòstic

T clínic	
1a	~
рТ	
	~
урТ	
	~
Estadi clínic	
	~
Clark	
	~

1	~
pN	
	~
ypN	
	~
Estadi patològic	
	~
Breslow	

	~
pM	
	~
урМ	
	~

#### Infecció H.Pylori







 $\sim$ 

### Hematologic transformation assistant

Data Incidència Hospitalària	Data Incidència Poblacional 📀	Data Mostra APA Hospital
03/05/2010	23/01/2019	23/01/2019
Topografia Q	Morfologia Q	Mètode Dx
C421 - MÉDUL.LA ÒSSIA 🗸	M-97323 - Mieloma de cèl·lules   🗸	7 - Biòpsia de tumor principal 🛛 🗸
Lateralitat 💡	Comité de tumors	Grau diferenciació 🤕
~	Sí 🗸 🗸	6: Cèl·lula B, Pre-B; precursor B 🛛 🗸
Grau Urològic 💡	Grau SNC 🍞	Grau Neuroendocrins
~	~	~
Transformació Hematològica		
Transformació Hematològica		
Segona Morfologia Q	Data Segona Morfologia	Topografia Q
M-96653 - Limfoma de Hodgkin, 🗸		~
Transformació hematològica 🥥		
Possible Múltiple 🗸		
Guardar		
Tornar a revisió		

#### **References:**

1.Gavin A, Rous B, Marcos-Gragera R, et al. Towards optimal clinical and epidemiological registration of haematological malignancies: Guidelines for recording progressions, transformations and multiple diagnoses. *Eur J Cancer*. 2015;51(9):1109-1122. http://dx.doi.org/10.1016/j.ejca.2014.02.008


2 Haemacare. Manual for Coding and Reporting Haematological Malignancies. In M. Sant, M.-L. Karjalainen-Lindsberg, M. Maynadié, M. Raphaël, S. Ferretti, A. Giacomin, C. Tereanu, P. Giraldo-Castellano, R. Marcos-Gragera, C. Martos-Jiménez, J.-M. Lutz, & O. Visser (Eds.), *Tumori*, 2010, Vol. 96, Issue 4.







# **Quality checks**




- Validates: Hospital incidence date, birth date, sex, topography, histology, behaviour, diagnostic method, degree of differentiation, TNM, pTNM, Stage, Gleason, Dukes, Figo Ann Arbor, Breslow, laterality, vital status and date of death. \*\* Validates: Date of diagnosis, treatment and death, taking into account the sequence of events.
- REF: JRC Technical Report: A common data quality check procedure for European cancer registries. Martos, Giusti, Van Eycken, Visser. 2024







# **Results (shiny portal)**










### **Observed survival example**

— I — II — III — IV — Estadi desconegut



	Observed survival (CI 95%)		
	1 year	5 years	10 years
I	95.49 (94.16-96.83)	79.59 (76.91-82.37)	63.40 (58.96-68.17)
Ш	93.67 (92.50-94.85)	76.21 (74.08-78.40)	56.99 (53.63-60.56)
Ш	90.10 (88.68-91.55)	61.52 (59.09-64.06)	45.05 (41.79-48.57)
IV	57.71 (55.40-60.10)	18.17 (16.34-20.20)	10.32 (8.48-12.57)
Estadi desconegut	72.39 (69.68-75.21)	49.31 (46.24-52.58)	39.47 (35.99-43.28)
**CI(95%):** 95% confidence interval			











